HOLLY SPRINGS, N.C. (January 20, 2026) — Genentech, a member of the Roche Group, announced it will more than double its investment in a new biomanufacturing facility in Holly Springs, North Carolina, increasing total capital commitment to approximately $2 billion. The expansion significantly scales production capacity at the company’s first East Coast manufacturing facility and strengthens Roche and Genentech’s broader $50 billion U.S. manufacturing and R&D investment strategy.
Construction on the facility began in August 2025 following an initial investment announcement earlier that year. The expanded project will allow for additional production lines and increased output, positioning the facility to support next-generation treatments for metabolic diseases, including obesity. The site is expected to become operational by 2029.
Major Job Creation and Supply Chain Expansion
The expanded investment is expected to support more than 2,000 jobs, including over 500 high-wage manufacturing positions and more than 1,500 construction jobs, reinforcing Genentech’s role as a major economic driver in the Research Triangle region.
By leveraging advanced biomanufacturing technologies, automation, and digital systems, the facility will enhance operational efficiency, sustainability, and resilience while significantly expanding Genentech’s U.S.-based supply chain.
Genentech cited the region’s highly skilled workforce, strong academic institutions, and proximity to a dense life sciences ecosystem as key factors behind the decision to further expand in Holly Springs.
Strengthening U.S. Biopharmaceutical Manufacturing
The investment aligns with Roche and Genentech’s long-term commitment to strengthening domestic pharmaceutical manufacturing. Across the United States, the companies operate 13 manufacturing facilities and 15 R&D sites, employing approximately 25,000 people across eight states.
“We are excited to further expand our investment in our state-of-the-art manufacturing facility in Holly Springs,” said Ashley Magargee, CEO of Genentech. “This expansion reflects our long-term commitment to the United States and to communities that offer world-class biotech talent, top research institutions, and strong infrastructure. This additional investment will create high-quality jobs, strengthen local partnerships, and help ensure a resilient supply of medicines for years to come.”
Magargee also acknowledged the role of public-sector collaboration in advancing the project, noting support from federal, state, and local leaders.
State and Local Leaders Applaud Expansion
Josh Stein praised the expansion as a catalyst for long-term economic growth.
“Genentech’s increased investment in Holly Springs creates durable jobs and strengthens North Carolina’s life sciences sector,” Stein said. “This expansion reinforces our state’s leadership in innovation, workforce development, and long-term opportunity.”
North Carolina Secretary of Commerce Lee Lilley added that the project underscores the state’s competitiveness in life sciences manufacturing, while Holly Springs Mayor Mike Kondratick called the expansion one of the most significant economic development initiatives in the town’s recent history.
About Genentech
Founded 50 years ago, Genentech is a leading biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious and life-threatening conditions. Headquartered in South San Francisco, California, Genentech is a member of the Roche Group.
